John Russel Denton bought $158k of CAI
See Remarks at Caris Life Sciences, Inc.. 7,500 shares at an average of $21.00, traded Jun 20, 2025, filed Jun 23, 2025.
Score components
- +15RoleOfficer
- +11Trade size$158k at market
- +3Relative to holdingsHoldings up 6%
- +10Price context0% above the 52-week low
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-061810, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2025 | DDisposition to issuer Common Stock | -238,230 | $18.60 | $4.4M | 16,770 | Jun 23, 2025 |
| Jun 18, 2025 | AGrant or award Common Stock | +99,321 | $0.00 | $0 | 116,091 | Jun 23, 2025 |
| Jun 20, 2025 | POpen-market purchase Common Stock | +7,500 | $21.00 | $158k | 123,591 | Jun 23, 2025 |
| Mar 3, 2025 | AGrant or award Stock Optionderivative | +255,000 | $0.00 | $0 | 255,000 | Jun 23, 2025 |
Related signals
Other insiders at Caris Life Sciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Caris Life Sciences, Inc. | John Russel Denton See Remarks | $239k 7,500 shares | -4% | |
| 60Notable | Caris Life Sciences, Inc. | Brian J Brille See Remarks | $12M 400,000 shares | -63% | |
| 48Moderate | Caris Life Sciences, Inc. | David Baxley Spetzler President | $15M 597,212 shares | -39% | |
| 59Moderate | Caris Life Sciences, Inc. | Brian J Brille See Remarks | $630k 30,000 shares | +23% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.